Amerisource Health Services DBA AME Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Amerisource Health Services DBA AME Pharmaceutical Import Records from India — 3 Products, $3.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amerisource Health Services DBA AME — Pharmaceutical Importer Profile (2026) | 3 Products, $3.3M Trade | TransData Nexus

Amerisource Health Services DBA AME

Pharmaceutical Importer · United States · Gastrointestinal Focus · $3.3M Total Trade · DGFT Verified

Amerisource Health Services DBA AME is a pharmaceutical importer based in United States with a total trade value of $3.3M across 3 products in 3 therapeutic categories. Based on 104 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Amerisource Health Services DBA AME sources from 6 verified Indian suppliers, with Glenmark Pharmaceuticals Limited accounting for 77.4% of imports.

Amerisource Health Services DBA AME — Import Portfolio & Supplier Network

Amerisource Health Services DBA AME import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Amerisource Health Services DBA AME?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Glenmark Pharmaceuticals Limited	$8.2M	240	77.4%
Cadila Healthcare Limited	$1.4M	49	13.1%
Lupin Limited	$478.0K

What Formulations Does Amerisource Health Services DBA AME Import?

Formulation	Value	Ships
Pharmaceuticals- gabapentin TAB 600MG	$900.0K	18
Pharmaceuticals- gabapentin TAB 800MG	$550.0K	11
Pharmaceuticals-ondansetron odt 4MG	$400.0K	8
Pharmaceuticals- potassium cl er TAB	$300.5K	10
Pharmaceuticals- gabapentin TAB 800MG	$300.0K	6
Pharmaceuticals- gabapentin TAB 600MG 500 (BP)	$300.0K	6
Pharmaceuticals zonisamide cap 100MG 100	$238.3K	5
Pharmaceuticals- ondansetron odt 4MG	$208.0K	5
Pharmaceuticals- gabapentin TAB 600MG	$200.0K	4
Pharmaceuticals-ondansetron odt 4MG	$182.3K	5
Pharmaceuticals fluconazole TAB 150MG 12ud	$150.4K	4
Pharmaceuticals potassium cl er TAB	$145.5K	4
Pharmaceuticals- zonisamide cap 100MG 500	$142.0K	3
Pharmaceutical medicine for human use-divalproex sodium er tabs 500 MG - 1 x	$131.2K	3
Pharmaceuticals- potassium cl er TAB	$116.6K	6

Amerisource Health Services DBA AME imports 200 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ondansetron	Gastrointestinal	$2.2M	64	1.8%	14
2	Fluconazole	Antifungals	$833.8K	35	0.9%	15
3	Atovaquone	Antimalarial & Antiparasitic	$250.0K	5	0.0%	14

Amerisource Health Services DBA AME imports 3 pharmaceutical products across 3 categories into United States totaling $3.3M.

Amerisource Health Services DBA AME — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Amerisource Health Services, operating under the trade name AME, is a U.S.-based pharmaceutical importer specializing in the procurement of finished pharmaceutical formulations from international markets, notably India. The company is headquartered in Columbus, Ohio, and functions as a key player in the U.S. pharmaceutical distribution network, focusing on sourcing and importing a diverse range of pharmaceutical products to meet domestic healthcare needs.

AME's role in the U.S. pharmaceutical supply chain is pivotal, as it bridges the gap between international manufacturers and domestic healthcare providers. By importing finished pharmaceutical formulations, AME ensures a steady supply of essential medications, contributing to the overall efficiency and resilience of the U.S. healthcare system. The company's operations are characterized by a commitment to quality, regulatory compliance, and timely delivery, aligning with the stringent standards set by U.S. regulatory bodies.

2Distribution Network

AME's distribution network is strategically designed to ensure efficient and reliable delivery of pharmaceutical products across the United States. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's operations are supported by advanced supply chain management systems that facilitate the seamless movement of goods from international suppliers to domestic healthcare providers. This infrastructure enables AME to maintain a consistent supply of medications, meeting the demands of various healthcare facilities nationwide.

The company's geographic coverage extends throughout the United States, ensuring that healthcare providers, including hospitals, clinics, and pharmacies, have access to a wide array of pharmaceutical products. AME's logistics capabilities are tailored to handle the complexities of importing finished pharmaceutical formulations, adhering to all regulatory requirements and industry best practices to guarantee product integrity and compliance.

3Industry Role

In the U.S. pharmaceutical supply chain, Amerisource Health Services DBA AME operates primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international manufacturers, particularly from India, AME plays a crucial role in diversifying the U.S. pharmaceutical market and enhancing the availability of various medications. This role is essential in ensuring that healthcare providers have access to a broad spectrum of pharmaceutical products, thereby supporting patient care and treatment outcomes.

AME's position as an importer and distributor allows it to influence the market by introducing a variety of products, including generics and specialized formulations, which can lead to competitive pricing and increased accessibility for patients. The company's operations are integral to the pharmaceutical supply chain, ensuring that imported products meet the necessary regulatory standards and are distributed efficiently to meet domestic demand.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Amerisource Health Services DBA AME

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Amerisource Health Services DBA AME's sourcing strategy exhibits a significant concentration on a select group of suppliers, particularly from India. The company's total import value from India stands at $3.3 million USD, encompassing 104 shipments and 200 unique formulations. This concentration indicates a strategic choice to leverage the cost-effectiveness and quality of Indian pharmaceutical manufacturers.

The top five products imported by AME include Ondansetron ($2.2 million, 1.8% market share), Fluconazole ($834,000, 0.9% market share), and Atovaquone ($250,000, 0.0% market share). These products are sourced from a limited number of suppliers, with GLENMARK PHARMACEUTICALS LIMITED accounting for 77.4% of the total import value, followed by CADILA HEALTHCARE LIMITED at 13.1%, and LUPIN LIMITED at 4.5%. This supplier concentration suggests a reliance on a few key partners for the majority of imported products.

While such concentration can lead to favorable pricing and streamlined logistics, it also presents potential risks. Any disruptions in the supply chain from these primary suppliers—due to regulatory issues, production challenges, or geopolitical factors—could impact AME's ability to meet domestic demand. Therefore, it is crucial for AME to assess and manage these risks by considering diversification strategies and maintaining robust contingency plans.

2Supply Chain Resilience

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that all drugs entering the U.S. market meet stringent standards for quality, safety, and efficacy. This oversight is governed by the Federal Food, Drug, and Cosmetic Act (FD&C Act), which outlines the requirements for drug approval, manufacturing practices, and importation procedures.

For Indian pharmaceutical manufacturers exporting to the U.S., obtaining FDA approval is mandatory. This process involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), depending on whether the product is a new chemical entity or a generic version of an existing drug. The FDA evaluates these applications to ensure that the products are safe and effective for their intended use. Additionally, the FDA conducts inspections of foreign manufacturing facilities to verify compliance with Good Manufacturing Practices (GMP) and other regulatory requirements.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. All foreign drug establishments whose products are imported must register with the FDA and list all their drug products intended for U.S. distribution. This registration process ensures that the FDA is notified of all regulated products entering the U.S. market. Furthermore, the FDA requires that imported drugs comply with the same standards for quality, safety, and effectiveness as domestically produced drugs. This includes adherence to Good Manufacturing Practices (GMP), which are guidelines that ensure products are consistently produced and controlled according to quality standards.

Frequently Asked Questions — Amerisource Health Services DBA AME

What products does Amerisource Health Services DBA AME import from India?

Amerisource Health Services DBA AME imports 3 pharmaceutical products across 3 categories. Top imports: Ondansetron ($2.2M), Fluconazole ($833.8K), Atovaquone ($250.0K).

Who supplies pharmaceuticals to Amerisource Health Services DBA AME from India?

Amerisource Health Services DBA AME sources from 6 verified Indian suppliers. The primary supplier is Glenmark Pharmaceuticals Limited (77.4% of imports, $8.2M).

What is Amerisource Health Services DBA AME's total pharmaceutical import value?

Amerisource Health Services DBA AME's total pharmaceutical import value from India is $3.3M, based on 104 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Amerisource Health Services DBA AME focus on?

Amerisource Health Services DBA AME imports across 3 categories. The largest: Gastrointestinal (66.9%), Antifungals (25.5%), Antimalarial & Antiparasitic (7.6%).

Get Full Amerisource Health Services DBA AME Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Amerisource Health Services DBA AME

Amerisource Health Services DBA AME — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Amerisource Health Services DBA AME?

What Formulations Does Amerisource Health Services DBA AME Import?

What Products Does Amerisource Health Services DBA AME Import?

Top Products by Import Value

Amerisource Health Services DBA AME Therapeutic Categories — 3 Specializations